SEC Form 4 · accession 0001127602-19-010115
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — Chief Patient Officer
Period of report
Feb 15, 2019
Accepted (ET)
Mar 5, 2019 · 7:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2019 | A | 330 | $57.4515 | A | 58,046 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $66.01 | Mar 1, 2019 | A | 9,640 | A | — | Mar 1, 2029 | Common Stock | 9,640 | 9,640 | D |
| Restricted Stock UnitF3,F4 | — | Mar 1, 2019 | A | 1,890 | A | — | — | Common Stock | 1,890 | 15,530 | D |
Explanation of responses
- F1Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
- F2The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- F3Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F4The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.